Source: Annual Congress 2004 - Community acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
T. T. Bauer, T. Pfeil, C. Ernen, D. Daniel, B. M. Schlosser, I. M. Thate-Waschke, R. Rychlik (Bochum, Burscheid, Leverkusen, Germany). Costs of treatment of hospitalised community-acquired pneumonia from the hospitals’ perspective – a prospective study comparing moxifloxacin with other antibiotic treatment alternatives. Eur Respir J 2004; 24: Suppl. 48, 1178

Member's Comments

No comment yet.

Related content which might interest you: Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial Source: Eur Respir J, 58 (2) 2002535; 10.1183/13993003.02535-2020 Year: 2021 Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 The extent of microbiological testing and antibiotic de-escalation in adults with community-acquired pneumonia: a retrospective cohort study. Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018 The effects of antibiotic therapy at the pre-hospital stage on the in-hospital mortality in adults with community-acquired pneumonia in Russia: observational study results. Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001 Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study Source: Eur Respir J, 54 (1) 1900057; 10.1183/13993003.00057-2019 Year: 2019 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 The impact of adherence to guidelines for hospitalized community-acquired pneumonia on health outcomes and mortality: A retrospective cohort study Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Antibiotic therapy of community-acquired pneumonia in the hospital setting: national guidelines and real clinical practice. Source: International Congress 2017 – COPD management Year: 2017 The impact of a stewardship programme on outcomes in patients admitted with community-acquired pneumonia Source: Virtual Congress 2020 – Antibiotic therapy for pneumonia and pleural infections Year: 2020 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis Source: Eur Respir J 2008; 31: 1068-1076 Year: 2008 Implementation of severity guided antibiotic treatment according to Dutch guidelines in hospitalized patients with community-acquired pneumonia (CAP) included in a clinical trial Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 GRACE-01 Genomics to combat resistance against antibiotics in community-acquired LRTI in Europe – a multicentre, observational cohort study of cough/LRTI in primary care Source: Annual Congress 2007 - Clinical trial: antibiotic use in the community Year: 2007 Comparative prospective cohort study of the efficacy and safety according to dose of Ceftriaxone in community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020